ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Allogeneic iPSC-derived CD58KO Anti-MICA/MICB CAR-ADR-expressing T-cells FT836

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Fate Therapeutics.

Furthest: phase 1, since Oct 8, 20251 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fate Therapeutics11 open or runningphase 1since Oct 8, 2025Oct 8, 2025Jan 2028phase 1 · NCT07216105

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 8, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07216105 · 119 planned · United States

Ahead

  1. Jan 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07216105

TargetBeta

“A preparation of allogeneic, off-the-shelf (OTS), T-lymphocytes derived from a clonal master induced pluripotent stem cell (iPSC) line, engineered and multiplex-edited to express both a chimeric antigen receptor (CAR) specific for the alpha 3 domain of the natural-killer group 2, member D receptor p”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07216105Carcinoma, Non-Small-Cell Lung · United States1RecruitingJan 2028119

How it is read

Names in the registry

  • “FT836”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.